Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity. 

Effective as of market opening on March 3, 2023, the upcoming reorganization will consist of the issuance of three additional common shares to everyone currently holding outstanding common shares. So the currently 2,413,431 issued and outstanding common shares will become approx. 9,653,724 common shares outstanding. 

The news comes after the recently announced launch of a new …

Full story available on